GAITHERSBURG, Md., March 28, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice President, Vaccine Development, will present, "Recombinant EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7th International Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. at the Washington Marriott Metro Center in Washington, D.C.
As part of his talk, Dr. Smith will present new data from a second non-human primate (NHP) study which was conducted by the National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases (NIH-NIAID-DMID). In that study, animals received two injections of a 5µg dose of Novavax' Ebola GP Vaccine together with its proprietary Matrix-M adjuvant and were then challenged with a lethal dose of the Ebola virus. Similar to the previous NHP study, the challenge was lethal for the control animals, whereas the animals immunized with Novavax' EBOV GP Vaccine remain healthy 18 days post challenge.
"This data provides significant, independent confirmation that our Ebola GP Vaccine is safe and effective in providing protection in NHP models," said Dr. Smith. "Our vaccine is the first subunit Ebola GP-based vaccine to provide protection in non-human primates and this confirmatory data strongly supports the advancement of this program. Importantly, although we developed our Ebola GP Vaccine from the Makona strain, which is the strain responsible for the recent Ebola epidemic in West Africa, these primates were challenged with the Kikwit strain of Ebola, which suggests that our vaccine candidate may be protective across different variants of the virus."
Novavax is currently conducting a Phase 1 clinical trial of its Ebola GP Vaccine in healthy subjects. It expects top-line data from this trial in mid-2015.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, www.novavax.com.
Statements contained in this release, including those relating to the closing of the offering, and those statements using words such as "expects" and "intends" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These risks and uncertainties include, but are not limited to: the possible adverse impact on the market price of our shares of common stock due to the dilutive effect of the securities to be sold in the offering; our planned use of the proceeds from this offering; capital market risks; our ability to raise additional capital when needed; and other risk factors identified from time to time in the reports we file with Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
CONTACT: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations firstname.lastname@example.org 240-268-2000